Saruparib for solid tumors with a DNA repair problem
Treatments studied
Part of Cancer clinical trials.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer that has spread or cannot be cured, and it is getting worse during the trial.
- A lab test shows your tumor has a specific DNA repair problem (called HRD positive).
- You have not had your cancer get worse within 6 months of platinum chemo (like cisplatin or carboplatin).
- You have never taken a PARP inhibitor before.
- You are generally able to do daily activities (ECOG score 0 or 1) and have adequate organ function.
- For one group (Cohort A), you also need a known change in genes like BRCA1, BRCA2, PALB2, or RAD51C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Hear when a new Malignant Neoplastic Disease (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.